Read by QxMD icon Read

Therapeutic Delivery

Simseok A Yuk, Diego A Sanchez-Rodriguez, Michael D Tsifansky, Yoon Yeo
Sepsis and septic shock are life-threating conditions, which form a continuum of the body's response to overwhelming infection. The current treatment consists of fluid and metabolic resuscitation, hemodynamic and end-organ support, and timely initiation of antibiotics. However, these measures may be ineffective and the sepsis-related mortality toll remains substantial; therefore, an urgent need exists for new therapies. Recently, several nanoparticle (NP) systems have shown excellent protective effects against sepsis in preclinical models, suggesting a potential utility in the management of sepsis and septic shock...
May 1, 2018: Therapeutic Delivery
Khaled Greish
Khaled Greish speaks to Hannah Makin, Commissioning Editor: Khaled Greish is Associate Professor of Molecular Medicine, and head of the Nano-research unit, at Princes Al-Jawhara Center, Arabian Gulf University, Kingdom of Bahrain. His previous appointments included Senior lecturer of Pharmacology at the University of Otago, New Zealand, and Assistant Professor of Pharmaceutical Chemistry at University of Utah (UT, USA). He has published >70 peer reviewed papers, and ten book chapters in the field of targeted anticancer drug delivery...
May 1, 2018: Therapeutic Delivery
F Philipp Seib
Silk is an important biopolymer for (bio)medical applications because of its unique and highly versatile structure and its robust clinical track record in human medicine. Silk can be processed into many material formats, including physically and chemically cross-linked hydrogels that have almost limitless applications ranging from tissue engineering to biomedical imaging and sensing. This concise review provides a detailed background of silk hydrogels, including silk structure-function relationships, biocompatibility and biodegradation, and it explores recent developments in silk hydrogel utilization, with specific reference to drug and cell delivery...
May 1, 2018: Therapeutic Delivery
Chandra S Sharma, Mudrika Khandelwal
No abstract text is available yet for this article.
May 1, 2018: Therapeutic Delivery
Sourav Bhattacharjee, Maria Manuela Gaspar, Dimitri Scholz, António J Almeida, David J Brayden
AIM:  To investigate how surface charge and hydrophilicity affect the mucopermeation of liposomes across intestinal mucus. METHODOLOGY: Rhodamine-labeled liposomes (∼120-130 nm) with different surface charges were investigated for their capacity to flux across fresh porcine jejunal mucus in a microchannel device. Fluorescent microscopy and tracking analysis were used to measure liposome movement, while fluorescence lifetime imaging microscopy was utilized to determine mucus pH...
May 1, 2018: Therapeutic Delivery
Gaurav Parekh, Yuanyuan Shi, Juanjuan Zheng, Xingcai Zhang, Stefano Leporatti
Theranostic approaches using nanotechnology have been a hot research area for the past decade. All nano drug delivery techniques and architectures have some limitations, as do diagnostic nano-approaches. Thus, combining nano drug delivery strategies with diagnostic techniques using nanoparticles for improving imaging modalities has been the key to fill up those gaps. In the past decade, lots of approaches have been made with different combinations of biomaterials fabricated/synthesized to nanostructures with modified surface functionalization to improve their overall theranostic properties...
May 1, 2018: Therapeutic Delivery
Oliver C Steinbach
The present industry update covers the period of 1 January-31 January 2018, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature. Several public offerings (Gecko, Insmed), licensing (Foresee) and commercialization agreements (Alnylam, Collegium Pharmaceutical) as well as patent filings (Elute) continue to prove the sustained investments in the drug delivery market. In increasing numbers, more effective ways to deliver the active ingredient to the right location and the right dose through devices (Boehringer Ingelheim's Respimat, Medtronics' SynchroMedII) or improved compound properties through formulation (Aquestive Therapeutics' PharmFilm, Noven Pharmaceuticals' transdermal patch) are reaching the market...
May 1, 2018: Therapeutic Delivery
Jennifer L Wylie, Aileen House, Peter J Mauser, Shari Sellers, Jenna Terebetski, Zhenyu Wang, Jason D Ehrick
The factors that influence inhaled first-in-human (FIH) device and formulation selection often differ significantly from the factors that have influenced the preceding preclinical experiments and inhalation toxicology work. In order to minimize the risk of delivery issues negatively impacting a respiratory pipeline program, the preclinical and FIH delivery systems must be considered holistically. This topic will be covered in more detail in this paper. Several examples will be presented that highlight how appropriate scientific strategy can help bridge the gap between delivering to preclinical species and human...
May 2018: Therapeutic Delivery
Justin J Y Tan, Lifeng Kang
No abstract text is available yet for this article.
May 2018: Therapeutic Delivery
Ankit Javia, Jitendra Amrutiya, Rohan Lalani, Vivek Patel, Priyanka Bhatt, Ambikanandan Misra
The management of wounds and burns is becoming difficult using conventional therapeutics available due to resistance development by microbes. Therefore, there is an utmost need to develop therapeutic alternatives to these agents. Antimicrobial peptides have emerged as a novel class of agents for the effective management of wounds and burns due to their potent nature along with minimal chances of resistance development against them. This article focuses on highlighting the importance of these antimicrobial peptides among the various therapeutic alternatives for burns and wounds...
May 2018: Therapeutic Delivery
Catarina Pinto Reis
The present industry update covers the period 1-31 December 2017. Information was sourced primarily from scientific literature and various news websites, company press releases, regulatory and patent agencies. The most representative (not all) examples of research are herein described and they are mainly focused on metabolic diseases, cancer, blood pressure diseases, eyes diseases and, in some cases, in rare diseases. In this paper, there was a clear positive approval tendency for several companies where they offered novel therapeutic delivery candidates...
May 2018: Therapeutic Delivery
Aroonsri Priprem, Chatchanok Nukulkit, Nutjaree P Johns, Supawan Laohasiriwong, Kwanchanok Yimtae, Cheardchai Soontornpas
AIM: A transmucosal niosome gel was developed to improve the pharmacokinetics of exogenous melatonin. MATERIALS & METHODS:  The melatonin niosomes (MN) gel was characterized and melatonin levels were determined in healthy volunteers. RESULTS: Micron-sized MN in a gel, mean ex vivo residence time of more than 3 h with maximum adhesiveness at 25 and 37°C showed similar in vitro release but different in vitro permeation to melatonin gel...
May 2018: Therapeutic Delivery
Rohini Singh, Shalini Gupta
No abstract text is available yet for this article.
May 2018: Therapeutic Delivery
Sucharat Limsitthichaikoon, Bhattaranitch Khampaenjiraroch, Teerasak Damrongrungruang, Wanwisa Limphirat, Suthasinee Thapphasaraphong, Aroonsri Priprem
AIM: An anthocyanin complex (AC), combined Zea mays and Clitoria ternatea extracts, was evaluated for topical oral wound healing in rats and a clinical trial in orthodontic patients. METHODS/RESULTS: AC enhanced anthocyanin permeation in vitro. In rats, 10% w/w of AC in a mucoadhesive gel (AG) reduced erythema and sizes of oral wounds after topical applications at higher extent than its placebo gel. Acute orthodontic wounds in 68 volunteers were randomly assigned to topically receive either AG or placebo gel and double-blind assessed...
May 2018: Therapeutic Delivery
Khaled Greish, Sebastien Taurin, Mohamed A Morsy
AIM: This study tested the effect of TNF-α, a cytokine associated with inflammation, and tumor progression, on enhancing doxorubicin (Dox) tumor accumulation, and improving its therapeutic effect. MATERIALS & METHODS: 4T1 murine breast cancer cells were injected into the flanks of Balb/c female mice and treated with TNF-α, Dox and a combination of both. RESULTS & CONCLUSION: The addition of TNF-α to Dox did not improve anticancer activity against 4T1 breast cancer cells in vitro...
May 2018: Therapeutic Delivery
Rinti Banerjee
No abstract text is available yet for this article.
March 2018: Therapeutic Delivery
Ya Xiao, Jiajia Huang, Jiajia Xu, Liuwei Zeng, Jiaran Tian, Yunru Lou, Yuxue Liu, Bo Hu, Fei Tong, Ruilin Shen
AIM: To synthesize a puerarin nanoparticle based on glycyrrhetinic acid (GA)-PEG-PBLA and evaluate it in vivo. MATERIALS & METHODS: In this study, drug nanoparticle was synthesized, characterized and assessed as puerarin delivery system. Nanoparticle GA-PEG-PBLA could combine with puerarin via hydrophobic interaction to form the compound. Puerarin could be quickly and efficiently loaded via the nanoparticle GA-PEG-PBLA at pH 7.4. Further, GA-PEG-PBLA-mediated puerarin delivery system could target for the liver that had GA receptor binding...
March 1, 2018: Therapeutic Delivery
Mariana Medina-Sánchez, Haifeng Xu, Oliver G Schmidt
Micro- and nano-motors are emerging as novel drug delivery platforms, offering advantages such as rapid drug transport, high tissue penetration and motion controllability. They can be propelled and/or guided by endogenous (i.e., chemotaxis) or exogenous stimuli (e.g., ultrasound, magnetic fields, light) toward the area of interest. Moreover, such stimuli can be used to trigger the release of a therapeutic payload when the motor reaches certain location in order to improve the drug targeting. In this review article, we highlight medically oriented micro-/nano-motors, in particular the ones created for targeted drug delivery, and discuss their current limitations and possibilities toward in vivo applications...
March 1, 2018: Therapeutic Delivery
Didem Şen Karaman, Suvi Manner, Jessica M Rosenholm
No abstract text is available yet for this article.
March 1, 2018: Therapeutic Delivery
Giuseppe Cavallaro, Giuseppe Lazzara, Rawil Fakhrullin
The review provides an overview of the mesoporous inorganic particles employed as drug delivery systems for controlled and sustained release of drugs. We have classified promising nanomaterials for drug delivery on the basis of their natural or synthetic origin. Nanoclays are available in different morphologies (nanotubes, nanoplates and nanofibers) and they are typically available at low cost from natural resources. The surface chemistry of nanoclays is versatile for targeted modifications to control loading and release properties...
March 1, 2018: Therapeutic Delivery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"